Pharsight

Ayvakit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9944651 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(10 years from now)

US9994575 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(10 years from now)

US9200002 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(10 years from now)

US11827642 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(10 years from now)

Ayvakit is owned by Blueprint Medicines.

Ayvakit contains Avapritinib.

Ayvakit has a total of 4 drug patents out of which 0 drug patents have expired.

Ayvakit was authorised for market use on 16 June, 2021.

Ayvakit is available in tablet;oral dosage forms.

Ayvakit can be used as treatment of indolent systemic mastocytosis (ism).

Drug patent challenges can be filed against Ayvakit from 10 January, 2024.

The generics of Ayvakit are possible to be released after 15 October, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-863) Jun 16, 2024
New Chemical Entity Exclusivity(NCE) Jan 09, 2025
New Indication(I-864) Jun 16, 2024
Orphan Drug Exclusivity(ODE-356) Jun 16, 2028
Orphan Drug Exclusivity(ODE-434) May 22, 2030
Orphan Drug Exclusivity(ODE-366) Jan 09, 2027
New Indication(I-912) May 22, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using AVAPRITINIB ingredient

NCE-1 date: 10 January, 2024

Market Authorisation Date: 16 June, 2021

Treatment: Treatment of indolent systemic mastocytosis (ism)

Dosage: TABLET;ORAL

More Information on Dosage

AYVAKIT family patents

Family Patents